BACKGROUND: Annual computed tomography (CT) scans are a component of the current standard of care for the posttreatment surveillance of survivors of colorectal cancer (CRC) after curative-intent resection. The authors conducted a retrospective study with the primary aim of assessing patient, physician, and organizational characteristics associated with the receipt of CT surveillance among veterans. METHODS: The Department of Veterans Affairs Central Cancer Registry was used to identify patients diagnosed with AJCC collaborative stage I to III CRC between 2001 and 2009. Patient sociodemographic and clinical (ie, CRC stage and comorbidity) characteristics, provider specialty, and organizational characteristics were measured. Hierarchical multivariable logistic regression models were used to assess the association between patient, provider, and organizational characteristics on receipt of 1) consistently guideline-concordant care (at least 1 CT every 12 months for both of the first 2 years of CRC surveillance) versus no CT receipt and 2) potential overuse (>1 CT every 12 months during the first 2 years of CRC surveillance) of CRC surveillance using CT. The authors also analyzed the impact of the 2005 American Society of Clinical Oncology update in CRC surveillance guidelines on care received over time. RESULTS: For 2263 survivors of stage II/III CRC who were diagnosed after 2005, 19.4% of patients received no surveillance CT, whereas potential overuse occurred in both surveillance years for 14.9% of patients. Guideline-concordant care was associated with younger age, higher stage of disease (stage III vs stage II), and geographic region. In adjusted analyses, younger age and higher stage of disease (stage III vs stage II) were found to be associated with overuse. There was no significant difference in the annual rate of CT scanning noted across time periods (year 2005 vs year > 2005). CONCLUSIONS: Among a minority of veteran survivors of CRC, both underuse and potential overuse of CT surveillance were present. Patient factors, but no provider or organizational characteristics, were found to be significantly associated with patterns of care. The
INTRODUCTION
Colorectal cancer (CRC) is a highly prevalent disease, with approximately 134,490 new cases and 49,190 deaths expected in the United States in 2016. 1 CRC is the second most commonly diagnosed cancer in females and the third most commonly diagnosed cancer in males. Approximately 80% of patients with CRC are diagnosed with nonmetastatic disease and undergo curative-intent surgical resection. 2, 3 Thus, across the US population, slightly more than 100,000 individuals will be added to the pool of survivors of CRC enrolled in surveillance each year. 1, 4 It is important to note that approximately 85% of CRC recurrences occur within the first 3 years after curative-intent surgery. 5 Computed tomography (CT) imaging detects 32% to 44% of recurrences, and 38% to 46% of patients with disease recurrence are candidates for potentially curative surgery. 6, 7 Curative resection can be successfully achieved for patients with liver metastases. 8, 9 Additional clinical evidence has demonstrated that the median progression-free survival is 5 months longer if treatment is initiated in asymptomatic patients compared with symptomatic patients. 10 Overall, the current evidence supports the role of annual CT surveillance by establishing that CRC recurrences can be detected earlier through surveillance and when treated result in better prognosis. Therefore, consensus guidelines from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network recommend an annual CT scan of the chest, abdomen, and pelvis over 3 years for the posttreatment surveillance of survivors of CRC after curative-intent surgery with or without adjuvant chemotherapy. [11] [12] [13] [14] The CRC posttreatment surveillance paradigm has changed over the last 2 decades. Clinical guidelines published by ASCO in 1999 stated, 15 "The data are sufficient to recommend against routine CT scanning in the followup of colorectal cancer." However, since then at least 5 randomized controlled trials (RCTs) [16] [17] [18] [19] [20] and 3 metaanalyses [21] [22] [23] published from 1995 through 2003 established that intensive CT surveillance is associated with reduced all-cause mortality. Although encumbered by methodological limitations, including the lack of a standard for body area imaging and different imaging modalities being used in different trials (ultrasound vs CT) as well as adjustment for stage of disease and changing practices in surgery 24, 25 and adjuvant chemotherapy, 26 these RCT findings led to changes in the surveillance approach recommended by ASCO in 2005 in favor of routine annual CT scans of the chest, abdomen, and pelvis (although it was openly recognized that there is less evidence for chest imaging) for the first 3 years after diagnosis for highrisk patients with CRC (mainly those with lymph nodepositive disease and the clinical assessment of a treating oncologist at the beginning of follow-up) treated with curative-intent surgery. 27 Given the existing evidence, CT surveillance can be considered a dimension of high-quality follow-up care among survivors of CRC. To better understand the current use of surveillance CT, we conducted a large retrospective study with the goal of assessing the patient, physician, and organizational characteristics associated with 1) underuse and 2) potential overuse of surveillance CT in the Veterans Health Administration (VA).
MATERIALS AND METHODS

Data Sources
Department of Veterans Affairs Central Cancer Registry
The Department of Veterans Affairs Central Cancer Registry (VACCR) was used to identify patients diagnosed with CRC between January 1, 2001 and September 30, 2009 . The VACCR uses trained registrars to collect information regarding all cancer diagnoses at hospital-based cancer registries within the VA since 1995.
VA administrative data
Cancer registry data were linked with VA administrative data regarding all outpatient visits and inpatient events from January 1, 2000 through September 30, 2011. The receipt of surveillance CT of the abdomen/pelvis, curative-intent surgical resection, and censoring events were identified using International Classification of Diseases, Ninth Revision (ICD-9) and Current Procedural Terminology, 4th Edition (CPT-4) codes (see Supporting Information Table 1 ).
Organizational survey
Patients were linked to VA facility survey data regarding organizational characteristics and capacity. The survey was supported by VA leadership as a component of an overall evaluation of the prevalence and predictors of high-quality care among veterans served in the Veterans Health Administration. 28, 29 The survey was directed toward Veteran Integrated Service Network chief medical officers, and the designated point of contact for each center was assigned according to the following categories: cancer committee chairperson (21% of facilities), division chief of hematology/oncology (39% of facilities), chief of staff (28% of facilities), or another physician (eg, surgeon; 12% of facilities). A total of 138 VA medical centers that agreed to participate were surveyed in December 2005 using a Web-based instrument that represented 88% of VA facilities in operation (157 facilities) at the time of administration.
Study Design
An observational, retrospective cohort study was performed among patients diagnosed with "AJCC collaborative stage" I, II, or III colorectal adenocarcinoma who underwent curative-intent surgical resection within 1 year of diagnosis. The primary outcome was to assess the receipt of surveillance CT within 2 years after curative-intent resection.
The start of the surveillance period (index date) was assigned to the date of curative-intent resection. To prioritize surgical over nonsurgical removal 30, 31 of CRC as indicating definitive curative-intent surgical resection, the index date was assigned to the following events in order of decreasing priority: 1) the earliest surgical removal of CRC within 180 days after the diagnosis date; 2) the latest surgical removal within the 30 days before the diagnosis date; 3) the earliest nonsurgical removal of CRC within 180 days after the diagnosis date; or 4) the latest nonsurgical removal of CRC within 30 days before the diagnosis date.
The main exclusion criteria were stage IV CRC, age <40 years at the time of diagnosis, or patients assigned to facilities with <10 patients with CRC (14 facilities). Therefore, patients from a total of 124 VA facilities were included in the final analytic cohort. Female patients also were excluded because the number (284 patients) and percentage of female patients (284 of 13,998 patients; 2.0%) were insufficient to estimate sex differences and therefore the findings would not be generalizable to care for women. In addition, patients were excluded if they were missing any data (median household income, provider type assignment, or organizational survey information) or were censored during the surveillance period. Patients were censored if the patient died within 3 years of diagnosis or if the patient experienced a CRC recurrence based on the receipt of chemotherapy at least 16 months after curativeintent resection (index date). In addition, patients were censored if they received radiotherapy or colorectal surgery at least 12 months after curative-intent resection (index date).
Outcome Measures (Dependent Variables)
The primary outcomes were receipt of 1) guidelineconcordant care and 2) potential overuse. For the primary outcome analyses, we included only the subset of patients with stage II or III CRC diagnosed in December 2005 or later. This decision was made because the 2005 ASCO guidelines first proposed surveillance CT for patients with stage II and stage III CRC, and thus we naturally wanted all patients to have their surveillance care assessed during a follow-up period over which the guidelines were constant (Fig. 1) . Surveillance CT was operationalized as CT of the abdomen/pelvis to provide the fairest estimate of guideline-concordant care (ie, provide physicians with the benefit of the doubt if they perceived the clinical evidence insufficient to support chest imaging).
Guideline-concordant care
Guideline-concordant care, or the receipt of recommended tests, was defined as 1 CT every 12 months. Guidelineconcordant care was defined so as to encompass in the negative outcome (guideline-concordant care indicator 0) the construct of underuse (ie, patients who do not receive the surveillance appropriate to their cancer diagnosis). Receipt of guideline-concordant care over the full 2-year follow-up period was defined as consistent (at least 1 CT every year for each of the 2 years of follow-up), inconsistent (at least 1 CT every year for only 1 of the 2 years), or none (no CT scans performed during the 2 years of follow-up).
Potential overuse
Potential overuse of testing was defined as >1 CT every 12 months. Overuse over the full 2-year follow-up period was defined as consistent (>1 CT every year for each of the 2 years of follow-up), inconsistent (>1 CT every year for only 1 of the 2 years), or none (>1 CT every year in neither of the 2 years of follow-up).
As a secondary outcome, the rate of surveillance CT before and after December 2005 (when ASCO began recommending surveillance CT) was assessed for all patients with CRC of stages I to III. Because the guidelines only apply to patients with stage II and III disease, patients with stage I CRC were included in the analyses as a reference group to establish a background time trend. The rate of surveillance was evaluated annually as the percentage of eligible patients who received any surveillance CT.
Patient, Provider, and Organizational Characteristics (Independent Variables)
Patient characteristics
The patient characteristics were divided into sociodemographic and clinical characteristics as follows.
Sociodemographic factorsPatient sex, race, and marital status were obtained from the VACCR and VA administrative data. When there was disagreement, registry data were used because of greater completeness. Patient age at the time of curative-intent surgical resection was obtained from administrative data alone. VA priority scores were used as a proxy of VA access. [32] [33] [34] Priority levels of 1 to 8 are assigned to all veterans in VA administrative data based on service-connected disability and income level. The priority level influences the amount of copayment for VA services. The priority level was combined into 4 categories: catastrophically disabled (values 1 and 4), moderate disability (scores 2, 3, and 6), Medicaid assistance/low income (score 5), and no service-connected disability (scores 7 and 8). Due to considerable missingness in the patient income variable in VA administrative data, patient income data were obtained by linking the patient's zip code of residence (obtained from VA administrative data) with US Census data and then assigning patients the median income of their zip code of residence.
Clinical factorsThe CRC stage and histology were obtained from the cancer registry. Patient comorbidity was assessed using a modified Charlson-Deyo comorbidity score applied to VA administrative data (ICD-9 codes) for 1 year before CRC diagnosis. 35 The comorbidity score was modified by excluding the cancer component because all patients subsequently were diagnosed with CRC.
Provider characteristics
Provider type was operationalized as the percentage of all physician visits over the 2-year period after the index date Original Article in which each survivor of CRC received care from primary care physicians, CRC-directed specialists (general or CRC surgeon, gastroenterologist, medical oncologist, or radiation oncologist), or other types of physicians. The 2-year window was chosen to correlate with the time period over which CT surveillance was being observed.
Organizational characteristics
The region (ie, East, Midwest, South, or West) and total number of beds in 2008 for each facility were obtained from the Federal Practitioner. 36 Each VA medical center also provided information regarding organizational characteristics through a facility survey (see Supporting Information Table 2 ). Each patient was assigned to the facility at which they had the most outpatient visits. For patients with an equal number of visits to multiple facilities, the facility at which the patient underwent the most procedures or tests was assigned. If there were no outpatient visits or tests or procedures, the facility at which curative-intent surgical resection was performed was assigned.
Broadly speaking, Donabedian posits, 37 and Casalino et al 38 have confirmed, that the structure of the health care organization influences the health care services delivered. More specifically, items in the survey were drawn from concepts of a hospital-based organizational taxonomy 39 into the adapted domains of complexity (American College of Surgeons Commission on Cancer accreditation, tumor boards, physician mix), centralization (oncologist verifies chemotherapy), human resources (support groups, sufficiency of nonphysician staffing [eg, nurses and case managers]), and technical capacity (availability of colonoscopy and positron emission tomography scan on site).
Statistical Analyses
For each of the outcomes of guideline-concordant care and potential overuse of CT surveillance, eligible survivors of CRC were classified into 3 subcohorts: consistent, inconsistent, and none. Descriptive statistics were presented for patient, provider, and organizational characteristics of the 3 subcohorts and pairwise comparisons were performed across the subcohorts, separately for guidelineconcordant care and potential overuse. The 2 outcomes were estimated and modeled separately. For assessing the outcome of guideline-concordant care, analyses were conducted to identify differences between 2 of the 3 subcohorts defined as "consistent" and "none" by their appropriate CT use. For assessing potential overuse, similar comparisons were made between the "none" subcohort (ie, no overuse) and a subcohort of "any overuse" defined by outcomes of "consistent" or "inconsistent" overuse. After bivariate analyses, multivariable logistic regression models estimated the association between independent variables (patient, provider, and organizational characteristics) and guideline-concordant care and potential overuse in separate models. The Wald test was used to test for overall significance (P<.05) among predictor variables with >2 categories before testing for the significance of individual variable categories (P<.05). To account for clustering of patients with CRC within medical facilities, multilevel models were fitted with generalized estimating equations.
For the secondary analyses, the impact of the 2005 ASCO update on CRC surveillance was analyzed by comparing the adjusted annual percentage of patients before and after 2005 using a logistic regression that modeled each eligible patient's probability of receiving CT scans over a 1-year period after their CRC diagnosis as a function of: 1) the calendar year; 2) preguideline versus postguideline (year 2005 vs year > 2005); and 3) stage of CRC (stage I vs stages II and III combined). We tested 2-way and 3-way interactions between all predictors to determine whether the rate of CT use changed with the onset of new guidelines and whether the change differed by CRC stage because the guidelines applied only to patients with stages II and III disease. All statistical analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, NC).
RESULTS
A total of 13,622 patients were diagnosed with stage I to III CRC from January 1, 2001 to September 30, 2009 and underwent curative-intent surgical resection. Of these, a total of 2263 patients were diagnosed with stage II to III CRC after December 2005, had a follow-up observation period of at least 2 years, and were not excluded or censored (Fig. 1) ; these patients formed the CT surveillance cohort among whom both the receipt of guidelineconcordant surveillance care and potential overuse were assessed. The mean age of this cohort was 67.2 years; approximately one-half were married (49.1%) and the majority of the individuals were nonblack (84.2%). The CRC stage was evenly split between stage II (52.6%) and stage III (47.3%).
Underuse of Guideline-Concordant Care
A total of 52.5% of survivors of CRC consistently received CT scans, 28.1% inconsistently received CT scans, and 19.4% received no CT scans in 2 years of surveillance. The patient sociodemographic and clinical characteristics, as well as the provider and organizational factors, associated with the receipt of guidelineconcordant care are described in Table 1 . In bivariate comparison, consistent receipt of surveillance CT (vs never received) was associated with decreasing age, no insurance, more advanced cancer stage, having a lower percentage of primary care provider visits, having a greater percentage of specialty care provider visits, facility region, and receiving care at a facility staffed by nurses with Oncology Nursing Society membership. In the other bivariate comparison, consistent receipt of surveillance CT (vs inconsistent receipt) was associated with more advanced cancer stage, lower comorbidity, and provider type.
The multivariable analyses (Table 2) found that the likelihood of receiving consistent versus no surveillance CT was higher with younger age (40- 
DISCUSSION
Overall, we found consistent potential overuse (14.9%) and no use (19.4%) of surveillance CT among a minority of survivors of CRC in the VA health system. Among older patients, the lower use of guideline-concordant care and potential overuse may be due in part to a reluctance to pursue more aggressive surveillance approaches among elderly populations. Older patients may have a greater illness burden that influences the clinical decision making among this group, although our models adjusted for comorbidity and cancer stage. Patients with stage III disease were more likely to receive CT surveillance than those with stage II disease, most likely due to a lack of clear guidelines for stage II disease. The understanding of stage II colon cancer has evolved during the time of the current study into a more heterogeneous group of cancers with several prognostic (presentation with obstruction or perforation, inadequately sampled lymph nodes, tumor penetration through visceral peritoneum, and the presence of lymphovascular or perineural invasion) and predictive (microsatellite instability) factors affecting management decisions. [40] [41] [42] It is possible that our surveillance cohort had more patients with low-risk stage II disease, resulting in less use of surveillance CT. There also were regional variations in guideline-concordant care. This finding is not unexpected given that geographic differences are common when assessing the quality of health care, 43 but such variations nonetheless reflect opportunities for performance improvement.
Prior research has explored the appropriate use of colonoscopy in the clinical setting of surveillance among patients with cancer (as opposed to cancer screening among a general population). In a large, population-based Surveillance, Epidemiology, and End Results-Medicare cohort following patients with stage I to stage III CRC who underwent surgical resection between 2001 and 2009, 44 high and temporally stable rates were observed for guideline-concordant surveillance colonoscopy: 76% in 2001 and 77% in 2007 among patients with stage I disease. Furthermore, the colonoscopy rates were approximately the same for patients with stage II and III disease (73.2% and 73.1%, respectively). Both of these findings diverge from the trends observed in the current study cohort wherein the percentage of patients receiving guideline-concordant CT scans (in at least 1 year) both increased over time and significant differences were found between survivors of stage II and stage III CRC (77.3% vs 84.1%). These findings highlight the need to study individual component tests (imaging, procedural, etc) of overall cancer surveillance programs separately to clearly understand the trends and predictive factors unique to each test. A relatively low percentage of patients had potential overuse in the VA (14.9%). Often, integrated delivery systems such as the VA are considered optimal clinical environments for minimizing inappropriate care because of the opportunity to coordinate clinical and administrative processes; furthermore, the VA health care system does not have the same malpractice 45 or fee-for-service 46 incentives that can distort test ordering. Generally, use of cancer-related imaging is lower in the VA health care system compared with fee-for-service Medicare. 47 Clearly, the reduction in the amount of unnecessary procedures is of high importance in a value-driven health care delivery environment.
Patient factors associated with potential overuse included higher stage of disease and lower patient age. Patients with higher stage disease possibly undergo more CT scans due to indeterminate findings resulting in closer follow-up intervals. Patient anxiety 48, 49 or physician discomfort with clinical uncertainty 50 also may play a role in the ordering of inappropriately frequent CT scans. Young patients may be especially anxious or vigilant due to the quality-adjusted life-years ahead, and indeed, younger patients in the current study cohort were more likely to receive potential overuse. 51 In our choice of language, we are careful to describe CT scans received at these more frequent intervals as "potential" overuse because there is a risk of confounding by indication in the current study, and some of these follow-up tests may have been performed for diagnostic purposes.
A significant percentage of patients with stage I disease received CT scans (Fig. 2) , perhaps because guidelines vary for stage I disease among different professional organizations. For example, until 2013, the National Comprehensive Cancer Network recommended CT scans among patients with stage I, II, and III disease, whereas ASCO, Cancer Care Ontario, and the European Society of Medical Oncology recommended CT scans only for patients with stage II and III disease, including after the guideline change in 2005. 27, [52] [53] [54] With the guidelines now in agreement, it will be interesting to discover whether physicians continue to order CT scans among patients with stage I disease in the future; it is quite possible that a significant percentage will continue to receive CT surveillance if physicians default to a more aggressive surveillance approach to better manage uncertainty.
One unique dimension of our modeling approach was the simultaneous modeling of patient characteristics possibly associated with surveillance care, along with provider and organizational characteristics. In bivariate analyses, some organizational characteristics were found to be significantly associated with either guideline-concordant care (Oncology Nursing Society membership) or overuse (certification by American College of Surgeons committee and not having a case manager on site). However, none of these organizational characteristics remained significant after adjustment for other patient, provider, and organizational characteristics. Several other organizational characteristics demonstrated no association with either guideline-concordant care or potential overuse in adjusted models, including the presence of a medical oncologist practice, general surgeon, or positron emission tomography scan services on site, or the implementation of multidisciplinary tumor boards. The latter finding is consistent with the work of others, namely Keating et al, who found no association between multidisciplinary tumor boards and the quality of cancer care in VA facilities. 29 Although many of the organizational factors assessed herein describe screening, diagnostic, or treatment resources or capacity, these same factors arguably may be related to the delivery of cancer surveillance, as we hypothesized herein. In fact, cancer medical services rarely have been designed to specifically meet posttreatment needs (perhaps with the exception of palliative care), in part because cancer survivorship has been identified as a unique portion of the cancer care continuum only recently. 55 Our negative findings suggest that we have not yet empirically identified the predictors of greatest impact, but nonetheless the unique nature of this linkage between organizational and clinical data make the findings informative to other groups trying to better understand the complex interaction between existing organizational oncology structures and the delivery of health care services to cancer survivors.
The findings of the current study contribute to a greater understanding of the relationship between physician specialty and the quality of care delivered to cancer survivors. Previous studies have shown that survivors of CRC are more likely to receive preventive care 56 (cholesterol screening and bone densitometry) and lifestyle modification 57 when seen by primary care physicians only. However, survivors of CRC were less likely to receive cancer-related screening (mammography, cervical cancer screening) when oncologists were not involved with follow-up care. 56 The results of the current study demonstrate a statistical trend toward greater specialist involvement (surgery, oncology, radiation oncology, or gastroenterology) being associated with more appropriate follow-up care specific to the cancer previously diagnosed. However, further study will be essential to conclusively establish the role of the provider in the surveillance care of survivors of CRC. We found no significant increase in the receipt of surveillance CT after the 2005 update in the ASCO guidelines, which recommended routine imaging in the form of surveillance CT among patients with stage II and III CRC. There are multiple potential explanations for this finding. Over the time period from 2001 to 2009, rates of CT testing were increasing both before and after changes in the guidelines. In fact, even before the change in the ASCO guidelines, large percentages of patients with stage II and III CRC already were undergoing surveillance CT (48.7% in 2004 vs 65.8% in 2006) (Fig. 2) . This general trend toward the greater use of high-cost imaging in the VA parallels national trends in the United States over a similar period; for example, CT imaging doubled in a large health plan from 1997 to 2006. 58 The results of the current study also are similar to those reported by Paulson et al, who found a negligible impact of the 2005 ASCO guideline change on CT surveillance while analyzing trends in CRC surveillance using Survival, Epidemiology, and End Results-Medicare data. 44 Nevertheless, to the best of our knowledge, this is the first study to analyze the effect of the 2005 guidelines on the VA population. The replication of this finding in the VA suggests that factors in addition to financial incentives (eg, radiology self-referral) likely drive the increased use of these technologies. Contributory factors to the increasing use of CT scans may include improved techniques that make them more clinically useful, patient-generated demand, professional norms among networks of physicians, and the convenient availability of the technology.
The current study has many strengths. First, the large nationwide sample size provided sufficient power with which to assess multiple levels of influence on the appropriateness of posttreatment surveillance CT scans. Second, we used a well-established cancer registry (VACCR) and administrative data for the ascertainment of receipt of CT, thereby minimizing any recall bias. Third, several steps were taken to avoid misclassification bias, such as using a stringent case definition (as described earlier) and including only those patients with at least 24 months of continuous enrollment after the date of diagnosis (index date). Fourth, we included many covariates, such as comorbidities and socioeconomic status (priority score and median income), which can be independently associated with care received.
There are several limitations associated with our approach. First, there was no information available regarding the indication for a provider ordering the CT scan due to the nature of administrative data. However, the risk of confounding by indication applies only to the overuse analyses, wherein a test may have been ordered for diagnostic purposes. However, this limitation does not impact the analyses of the underuse of guideline-concordant care, wherein underuse occurs only when no test is received at all, regardless of indication. Second, although guidelines recommend annual CT surveillance for the first 3 years after curative-intent therapy, we focused on CT surveillance data for the first 2 years. This decision was made largely because each successive year of follow-up demonstrated a substantial drop in both the percentage of patients who received as well, as the number of patients eligible, to receive surveillance CT (75% of 3839 patients in year 1, 60% of 2444 patients in year 2, and 52% of 1472 patients in year 3) and therefore years 1 and 2 were not combined with year 3 to avoid an overly heterogeneous population measure. Third, the current study included only male VA patients and therefore the external validity is limited to similar populations, at least in terms of sex. In addition, veterans aged 65 years may be more likely to receive care outside of the VA system due to Medicare coverage, and therefore the age differences found in surveillance CT scans may be due to underascertainment among older age groups. Fourth, we were unable to further differentiate survivors of stage II CRC based on their prognostic and predictive factors as discussed earlier. Finally, if it was not possible to ascertain CRC recurrence from the administrative data (eg, patients who developed disease recurrence but did not receive any additional therapy), the follow-up observation period then would continue beyond the true point of disease recurrence. Thus, the "none" category in the "guideline-concordant" surveillance outcome may be an overestimate.
CT imaging adds significant cost to the surveillance strategy for detecting early, potentially resectable CRC recurrences. Therefore, the use of intensive surveillance with imaging should be restrained among patients who are poor candidates due to risk of physical (eg, radiation exposure) and psychological (eg, anxiety) harms. A Cochrane systematic review of RCTs among survivors of stage II and stage III CRC concluded that even though intensive follow-up results in improvements in overall survival, its effects on costs, other harms, and quality of life could not be addressed due to the lack of sufficient data. 59 The treating oncologist and patient should assess the value of surveillance CT on a case-by-case basis. ASCO recommends against surveillance CT if the patient is not a candidate for curative surgical resection. 27 It also is important to note that the cost of screening CT scans has decreased over the past few years whereas availability has increased. 60 The current large study assessed the quality of CT surveillance in survivors of CRC who were treated with curative intent in the large integrated delivery system of the VA. We found no significant differences in the annual rate of CT scanning between patients with different stages of disease (stage I vs stages II and III) across time periods (year 2005 vs year > 2005). Younger age and more advanced stage of disease were found to be significant predictors of both potential overuse and underuse of guideline-concordant care. In terms of quality, this use pattern translated into both a lack of guidelineconcordant care (underuse) in 19.4% patients and inappropriate care (overuse) in 14.9% of patients.
